Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer

Yan Gao; Rosemary Foster; Xiaoqian Yang; Yong Feng; Jacson K. Shen; Henry J. Mankin; Francis J. Hornicek; Mansoor M. Amiji; Zhenfeng Duan

doi:10.18632/oncotarget.3220

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer

Yan Gao _, Rosemary Foster, Xiaoqian Yang, Yong Feng, Jacson K. Shen, Henry J. Mankin, Francis J. Hornicek, Mansoor M. Amiji and Zhenfeng Duan

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:9313-9326. https://doi.org/10.18632/oncotarget.3220

Metrics: PDF 2479 views | HTML 3525 views | ?

Abstract

Yan Gao1,2, Rosemary Foster3, Xiaoqian Yang1,2, Yong Feng1, Jacson K. Shen1, Henry J. Mankin1, Francis J. Hornicek1, Mansoor M. Amiji4, Zhenfeng Duan1

1Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA

2Department of Gynecology and Obstetrics, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China

3Vincent Center for Reproductive Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA

4Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, MA 02114, USA

Correspondence to:

Zhenfeng Duan, e-mail: [email protected]

Keywords: ovarian cancer, CD44, tissue microarray, Pgp, paclitaxel

Received: November 22, 2014 Accepted: January 26, 2015 Published: March 13, 2015

ABSTRACT

The clinical significance of Cluster of Differentiation 44 (CD44) remains controversial in human ovarian cancer. The aim of this study is to evaluate the clinical significance of CD44 expression by using a unique tissue microarray, and then to determine the biological functions of CD44 in ovarian cancer. In this study, a unique ovarian cancer tissue microarray (TMA) was constructed with paired primary, metastatic, and recurrent tumor tissues from 26 individual patients. CD44 expression in TMA was assessed by immunohistochemistry. Both the metastatic and recurrent ovarian cancer tissues expressed higher level of CD44 than the patient-matched primary tumor. A significant association has been shown between CD44 expression and both the disease free survival and overall survival. A strong increase of CD44 was found in the tumor recurrence of mouse model. Finally, when CD44 was knocked down, proliferation, migration/invasion activity, and spheroid formation were significantly suppressed, while drug sensitivity was enhanced. Thus, up-regulation of CD44 represents a crucial event in the development of metastasis, recurrence, and drug resistance to current treatments in ovarian cancer. Developing strategies to target CD44 may prevent metastasis, recurrence, and drug resistance in ovarian cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3220

Publication Alerts

Research Papers:

Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer

Abstract